LONDON, BOSTON, TOKYO & SAN DIEGO--(BUSINESS WIRE)--Record breaking new drug approvals, a hefty product pipeline and dramatically improved R&D productivity that has kept expenditure growth below sales growth prove that the industry is turning a new corner, according to Evaluate’s “World Preview 2014, Outlook to 2020” report.
“This much improved growth outlook comes as welcome news after two years of actual sales stagnation,” said Paul Hills, report author and Evaluate’s head of operations. “While the patent cliff is now but a distant memory, a new debate over drug pricing is stirring up controversy. This will only intensify as the industry continues to shift away from primary care and new technology waves offer innovative products that potentially take costs out of healthcare.”
The “World Preview 2014, Outlook to 2020” report, based on market intelligence and consensus forecasts from EvaluatePharma, can be downloaded at www.evaluategroup.com/wp2014. A hard-copy Executive Summary of the report is available at EvaluatePharma’s Booth #2521 at the 2014 BIO International Convention.
About Evaluate Ltd.
Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. We support life science and healthcare companies, financial institutions, consultancies and service providers in their strategic decision-making. Our services include EvaluatePharma, EvaluateClinical Trials and EvaluateMedTech. Our global team of dedicated healthcare analysts employs rigorous methodologies to deliver strategic commercial analysis. We make our services valuable by combining superior quality content, user-friendly reporting tools and outstanding customer service to solve client problems. Our award-winning editorial team, EP Vantage, leverages our market intelligence and analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.